VIDEO: OTX-TKI moves toward phase 3 trial for treatment of diabetic retinopathy
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for OTX-TKI, a tyrosine kinase inhibitor designed to block VEGFR-1, VEGFR-2 and VEGFR-3.
OTX-TKI (axitinib intravitreal implant, Ocular Therapeutix) is being evaluated in two phase 3 trials, SOL-1 and SOL-R, for the treatment of wet age-related macular degeneration. Kaiser shared data from the phase 1 HELIOS trial that showed stability or improvement in diabetic retinopathy at 1 year after treatment with the implant.
Patients also saw improvements in diabetic macular edema, Kaiser said.
“We will be starting a diabetic retinopathy phase 3 clinical study this year,” Kaiser said.
Collapse
Healio Interviews